Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.

William K Kelly,Daniel C Danila,Chia-Chi Lin,Jae-Lyun Lee,Nobuaki Matsubara,Patrick J Ward,Andrew J Armstrong,David Pook,Miso Kim,Tanya B Dorff,Stefanie Fischer,Yung-Chang Lin,Lisa G Horvath, Christopher Sumey,Zhao Yang, Gabor Jurida, Kristen M Smith, Jamie N Connarn,Hweixian L Penny,Julia Stieglmaier,Leonard J Appleman

Cancer discovery（2023）

引用 0|浏览11

暂无评分

摘要

Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer.

查看译文

关键词

prostate cancer,immune therapy,castration-resistant,first-in-human

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要